Impact of the Quality assured Mamma Diagnostic (QuaMaDi) programme on survival of breast cancer patients

Cancer Epidemiology

Volumn 35, Issue 3, 2011, Pages 286-292

  Obi, Nadia ^a   Waldmann, Annika ^a   Schäfer, Fritz ^b   Schreer, Ingrid ^b   Katalinic, Alexander ^a,c  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Epidemiological Cancer Registry Schleswig Holstein   (Germany)

Author keywords

Breast cancer; Cancer registry; Diagnostic programme; Mortality; Quality assurance; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ECHOMAMMOGRAPHY; FEMALE; GERMANY; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; QUALITY ASSURED MAMMA DIAGNOSTIC PROGRAMME; SURVIVAL RATE;

AGED; BREAST NEOPLASMS; FEMALE; GERMANY; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; QUALITY ASSURANCE, HEALTH CARE; REGISTRIES; SURVIVAL RATE;

EID: 79955987906     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2010.09.001     Document Type: Article

References (34)

1. Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. [Cancer in Germany 2005/2006. Frequencies and trends.]. 7. 2010. Berlin, Robert Koch-Institut (Ed.) und die Gesellschaft der Epidemiologischen Krebsregister in Deutschland e.V. (Ed.).
2. Pritzkuleit R, Holzmann M, Raspe H, Katalinic A. Krebs in Schleswig-Holstein. Inzidenz und Mortalität im Jahr 2006. Band 7; 2009. Lübeck, Institut für Krebsepidemiologie e.V.
3. Katalinic A., Bartel C., Raspe H., Schreer I. Beyond mammography screening: quality assurance in breast cancer diagnosis (The QuaMaDi Project). Br J Cancer 2007, 96(1):157-161.
4. Katalinic A., Pritzkuleit R., Waldmann A. Recent trends in breast cancer incidence and mortality in Germany. Breast Care 2009, 4(2):75-80.
5. Schaefer F.K., Waldmann A., Katalinic A., Wefelnberg C., Heller M., Jonat W., et al. Influence of additional breast ultrasound on cancer detection in a cohort study for quality assurance in breast diagnosis-analysis of 102,577 diagnostic procedures. Eur Radiol 2009, 20(5):1085-1092.
6. Albert U.S., Schulz K.D. Short version of the Guideline: Early Detection of Breast Cancer in Germany. An evidence-, consensus-, and outcome-based guideline according to the German Association of the Scientific Medical Societies (AWMF) and the German Agency for Quality in Medicine (AeZQ). J Cancer Res Clin Oncol 2004, 130(9):527-536.
7. Obi N., Waldmann A., Babaev V., Katalinic A. Record linkage of a large clinical practice patient cohort with the cancer registry Schleswig-Holstein. Gesundheitswesen 2010.
8. EUREF European guidelines for quality assurance in breast cancer screening and diagnosis 2006, Luxembourg, European Communities. 4th. N. Perry, M. Broeders, C. de Wolf, S. Törnberg, R. Holland, L. von Karsa (Eds.).
9. Garson G.D. Cox regression: assumptions. Cox regression: statnotes, from North Carolina State University 2010, Public Administration Program, [cited 2010 June 10]; URL: http://faculty.chass.ncsu.edu/garson/PA765/cox.htm#assume.
10. Krzyzanowska M.K., Tannock I.F. Should screen-detected breast cancers be managed differently?. J Natl Cancer Inst 2005, 97(16):1170-1171.
11. Black W.C., Haggstrom D.A., Welch H.G. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002, 94(3):167-173.
12. Lawrence G., Wallis M., Allgood P., Nagtegaal I.D., Warwick J., Cafferty F.H., et al. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat 2009, 116(1):179-185.
13. Shen Y., Yang Y., Inoue L.Y., Munsell M.F., Miller A.B., Berry D.A. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005, 97(16):1195-1203.
14. Duffy S.W., Nagtegaal I.D., Wallis M., Cafferty F.H., Houssami N., Warwick J., et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol 2008, 168(1):98-104.
15. Dong W., Berry D.A., Bevers T.B., Kau S.W., Hsu L., Theriault R.L., et al. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the University of Texas M. D. Anderson Cancer Center Experience. Cancer Epidemiol Biomarkers Prev 2008, 17(5):1096-1103.
16. Richter M., Brand H., Rossler G. Socio-economic differences in the utilisation of screening programmes and health promotion measures in North Rhine-Westphalia, Germany. Gesundheitswesen 2002, 64(7):417-423.
17. Gentil-Brevet J., Colonna M., Danzon A., Grosclaude P., Chaplain G., Velten M., et al. The influence of socio-economic and surveillance characteristics on breast cancer survival: a French population-based study. Br J Cancer 2008, 98(1):217-224.
18. Smith E.R., Adams S.A., Das I.P., Bottai M., Fulton J., Hebert J.R. Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality. Cancer Epidemiol Biomarkers Prev 2008, 17(10):2882-2890.
19. Eaker S., Halmin M., Bellocco R., Bergkvist L., Ahlgren J., Holmberg L., et al. Social differences in breast cancer survival in relation to patient management within a National Health Care System (Sweden). Int J Cancer 2009, 124(1):180-187.
20. Yu X. Socioeconomic disparities in breast cancer survival: relation to stage at diagnosis, treatment and race. BMC Cancer 2009, 9(1):364.
21. Hancke K., Denkinger M.D., Konig J., Kurzeder C., Wockel A., Herr D., et al. Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 2009, 21(4):748-753.
22. Wishart G.C., Greenberg D.C., Britton P.D., Chou P., Brown C.H., Purushotham A.D., et al. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?. Br J Cancer 2008, 98(11):1741-1744.
23. Voordeckers M., Vinh-Hung V., Van de S.J., Lamote J., Storme G. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 2004, 70(3):225-230.
24. Blamey R.W., Hornmark-Stenstam B., Ball G., Blichert-Toft M., Cataliotti L., Fourquet A., et al. ONCOPOOL-a European database for 16,944 cases of breast cancer. Eur J Cancer 2010, 46(1):56-71.
25. Ward S., Pilgrim H., Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Health Technol Assess 2009, 13(Suppl. 1):1-6.
26. Lash T.L., Silliman R.A., Guadagnoli E., Mor V. The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer 2000, 89(8):1739-1747.
27. Hebert-Croteau N., Brisson J., Latreille J., Rivard M., Abdelaziz N., Martin G. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 2004, 22(18):3685-3693.
28. Wockel A., Kurzeder C., Geyer V., Novasphenny I., Wolters R., Wischnewsky M., et al. Effects of guideline adherence in primary breast cancer-a 5-year multi-center cohort study of 3976 patients. The Breast 2010, 19(2):120-127.
29. Joensuu H., Lehtimaki T., Holli K., Elomaa L., Turpeenniemi-Hujanen T., Kataja V., et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004, 292(9):1064-1073.
30. Houssami N., Ciatto S., Martinelli F., Bonardi R., Duffy S.W. Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol 2009, 20(9):1505-1510.
31. Schrag D. Enhancing cancer registry data to promote rational health system design. J Natl Cancer Inst 2008, 100(6):378-379.
32. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J., et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009, 20(8):1319-1329.
33. Brucker S.Y., Schumacher C., Sohn C., Rezai M., Bamberg M., Wallwiener D. Benchmarking the quality of breast cancer care in a nationwide voluntary system: the first five-year results (2003-2007) from Germany as a proof of concept. BMC Cancer 2008, 8:358-370.
34. Silliman R.A. Crossing the quality chasm in breast cancer care. J Clin Oncol 2004, 22(18):3654-3656.